Discover the 10 best Infrastructure as Code (IaC) tools for DevOps teams in 2025. Learn how these tools enhance automation, stability, and scalability in cloud environments. Improve your deployment ...

Stop wasting time on generic gifts nobody remembers. Learn how to make DIY Christmas presents that are fast, simple, and guaranteed to impress. These ideas work for family, friends, or even ...

remove-circle Internet Archive's in-browser video "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see your ...

On October 3, 2025, the U.S. Food and Drug Administration (FDA) announced a prioritization pilot program for reviewing abbreviated new drug applications (ANDAs). ANDAs are submissions for generic ...

remove-circle Internet Archive's in-browser video "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see your ...

Abstract: Mobile Crowdsensing (MCS) has become a popular sensing paradigm, where a number of participants use their mobile devices to collectively share and extract information related to a certain ...

This latest FDA program aims to provide speedier reviews for generic drugmakers who produce their products in the U.S. Keeping up its string of pilots in recent months, the FDA on Friday unwrapped a ...

Big pharmaceutical companies are boosting their production capacity of branded medications with billions of dollars in new U.S. manufacturing plant construction, but generic drug production still ...

The U.S. Food and Drug Administration has introduced a new pilot program aimed at accelerating the review process for generic drugs that are both tested and produced entirely within the United States.

Oct 3 (Reuters) - The U.S. Food and Drug Administration said on Friday it has launched a new pilot program to speed up the review process for generic drugs that are tested and manufactured entirely in ...

Against a backdrop of tariff updates and a drug pricing deal from the Trump administration, the FDA charted a pair of moves this week in its push to make drug manufacturing more attractive in the U.S.